Brief: Fibrobiologics Completes Site Onboarding For Phase 1/2 Clinical Trial For Cywc628 For The Treatment Of Refractory Diabetic Foot Ulcers
05/03/2026 13:33
March 5 (Reuters) - Fibrobiologics Inc FBLG.O: FIBROBIOLOGICS COMPLETES SITE ONBOARDING FOR PHASE 1/2 CLINICAL TRIAL FOR CYWC628 FOR THE TREATMENT OF REFRACTORY DIABETIC FOOT ULCERS Source text: ID:nGNX6f2DLV Further company coverage: FBLG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts